In addition, loss of KMT5A catalytic activity by KMT5A depletion or KMT5A-selective inhibitor combined with YAP signaling inhibition impedes breast cancer progression using a mouse xenograft model of breast cancer metastasis. This evidence concerns the gene KMT5A and breast carcinoma.